Severe headache in primary Sjögren’s syndrome responded to rituximab
  • Maysoun Kudsi
    Rheumatology Department, Faculty of Medicine, Damascus University, Damascus, Syria
  • Ghina Haidar
    Rheumatology Department, Faculty of Medicine, Damascus University, Damascus, Syria
  • Batoul Hadid
    Rheumatology Department, Faculty of Medicine, Damascus University, Damascus, Syria
  • Enas Roumieh
    Rheumatology Department, Faculty of Medicine, Damascus University, Damascus, Syria
  • Safaa Al-Sayed
    Rheumatology Department, Faculty of Medicine, Damascus University, Damascus, Syria

Keywords

Rituximab, Headache, Primary Sjögren’s syndrome

Abstract

Introduction: Primary Sjögren syndrome (pSS) is an immune systemic disease, that may affect the central nervous system. A severe headache unresponsive to treatment is the headache which is persistently nonresponsive to narcotic analgesics.
Case presentation: A 48-year-old woman with a 10-year history of pSS was seen in January 2021, complaining of a headache one week previously. The headache was characterised by a dull persistent pressing intensity and was not responding to paracetamol, NSAIDs or codeine. She had no previous history, nor family history. Physical examination revealed bilateral parotid glands enlargement. Laboratory tests showed anaemia, and elevated levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), with positive anti-La and anti-Ro antibodies. She was given topical treatment and different doses of Predlone, in addition to methotrexate10 mg/week. She had received three pulses of methylprednisolone and was started on azathioprine with a mild response to the headaches, so she received two initial IV doses of rituximab 375 mg/m2, then every 2 weeks, with a clinical and laboratory response. Two years later, she had no headache.
Discussion: Headache that may presented in pSS are tension headaches, migraines and cluster headaches. The therapy is disease-modifying antirheumatic drugs, hydroxychloroquine, glucocorticoids and biotherapeutics. Rituximab is used in the treatment of some patients with pSS, especially where it can affect systemic symptoms.
Conclusion: Rituximab treatment may be an option for severe headache in patients with pSS. The mechanism is unknown but may be due to depletion of brain auto-reactive B cells. Further research is needed.

VIEW THE ENTIRE ARTICLE

References

  • Khalayli N, Kudsi M. Sjögren’s syndrome with bipolar disorder, case report. Ann Med Surg (Lond) 2022;80:104243.
  • Tjensvoll AB, Lauvsnes MB, Norheim KB, Omdal R. Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab. Clin Case Rep 2019;7:416– 418.
  • Cocores AN, Monteith TS. Headache as a neurologic manifestation of systemic disease. Curr Treat Options Neurol 2022;24:17–40.
  • Morreale M, Marchione P, Giacomini P, Pontecorvo S, Marianetti M, Vento C, et al. Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PLoS One 2014;9:e84605.
  • Biscetti L, De Vanna G, Cresta E. Corbelli I, Gaetani L, Cupini L, et al. Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. J Neuroinflammation 2021;18:259.
  • Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76: 9–16.
  • Khalayli N, Bouri MF, Wahbeh M, Drie T, Kudsi M. Neurological injury in primary Sjogren’s syndrome. Ann Med Surg (Lond) 2023;85:3381–3385.
  • Gökçay F, Oder G, Celebisoy N, Gökçay A, Sirin H, Kabasakal Y. Headache in primary Sjögren’s syndrome: a prevalence study. Acta Neurol Scand. 2008;118:189–192.
  • Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 2009;9:845–857.
  • Pal B, Gibson C, Passmore J, Griffiths ID, Dick WC. A study of headaches and migraine in Sjögren’s syndrome and other rheumatic disorders. Ann Rheum Dis 1989;48:312–316.
  • Johnsen SJ, Berget E, Jonsson MV, Helgeland L, Omdal R, Jonsson R. Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjögren syndrome with and without lymphoma. J Rheumatol 2014;4:2214–2222.
  • Mitsdoerffer M, Peters A. Tertiary lymphoid organs in central nervous system autoimmunity. Front Immunol 2016;7:451.
  • Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Pathogenesis and treatment of Sjogren’s syndrome: review and update. Front Immunol 2023;14:1127417.
  • Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. The value of rituximab treatment in primary Sjögren’s syndrome. Clin Immunol 2017;182:62–71
  • Chen YH, Wang XY, Jin X, Yang Z, Xu J. Rituximab therapy for primary Sjögren’s syndrome. Front. Pharmacol 2021;12:731122.
  • Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis 2007;66:351–357
  • Venkatesh AN, Muley S. Response of Sjogren-related small fiber neuropathy to rituximab. Neurology 2022; 99: doi: 10.1212/01.wnl.0000903332.92612.04

    • Views: 531
    HTML downloads: 762
    PDF downloads: 610

    Published: 2023-09-05
    Issue: 2023: Vol 10 No 10 (view)

    How to cite:
    1.
    Kudsi M, Haidar G, Hadid B, Roumieh E, Al-Sayed S. Severe headache in primary Sjögren’s syndrome responded to rituximab. EJCRIM 2023;10 doi:10.12890/2023_004051.